HER2 Support Group Forums - View Single Post - Genentech disappointed with FDA ODAC's recommendation against Avastin

News · 07-20-2010, 11:33 PM

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label.

More...

07-20-2010, 11:33 PM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,053	Genentech disappointed with FDA ODAC's recommendation against Avastin Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label. More...